View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 31, 2011

Ceridia Completes CER006 Drug Trial

Australian-based Ceridia has completed the Phase I human clinical study of its LipoCeramic ibuprofen formulation, CER006. The four-arm, blinded study demonstrated the safety and tolerability of CER006 in humans. The trial also suggested fast and improved delivery of ibupro

By cms admin

Australian-based Ceridia has completed the Phase I human clinical study of its LipoCeramic ibuprofen formulation, CER006.

The four-arm, blinded study demonstrated the safety and tolerability of CER006 in humans.

The trial also suggested fast and improved delivery of ibuprofen compared with the branded market leader.

Based on the study data, Ceridia plans to conduct bio-equivalence and bioavailability trials, which will include anti-inflammatory, anti-infective and oncology drugs.

The company is now planning to initiate a number of Phase II studies with the aim of reformulating and improving the clinical profiles of several therapeutic drugs.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology